High systemic immune–inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma

Figures & data

Table 1 Prognostic analysis of MPM patients

Variables	O/N*	Univariate	Analysis		Multivariate	Analysis
MST (months)	95% CI	P-value	HR (95% CI)	P-value
Age (years)				0.062		0.926
<65	41/76	21.5	15.336–27.664		1.00 (reference)
≥65	17/21	13.7	8.549–18.851		0.959 (0.400–2.301)
Gender				0.832		0.773
Male	36/58	21.5	16.595–26.405		1.00 (reference)
Female	22/39	16.0	12.785–19.215		1.099 (0.580–2.081)
Smoking				0.967		0.747
Never	39/64	17.5	13.229–21.771		1.00 (reference)
Ever	19/33	24.0	11.779–36.221		1.117 (0.570–2.187)
PS				<0.001		0.036
<2	52/91	21.5	15.020–27.980		1.00 (reference)
≥2	6/6	1.5	0.000–5.305		3.573 (1.085–11.765)
Primary site of tumor				0.777		0.892
Left	25/44	19.0	10.316–27.684		1.00 (reference)
Right	33/53	18.5	9.850–27.150		1.039 (0.594–1.817)
Pleural effusion				0.996		0.710
Absence	8/14	14.0	1.781–26.219		1.00 (reference)
Presence	50/83	18.5	12.052–24.948		0.858 (0.384–1.921)
Weight loss				0.629		0.580
No	49/79	17.3	13.262–21.738		1.00 (reference)
Yes	9/18	23.0	10.253–35.747		1.237 (0.582–2.630)
SII				<0.001		0.009
<988.6	17/44	47.0	15.020–27.980		1.00 (reference)
≥988.6	41/53	13.0	0.000–5.305		2.298 (1.232–4.289)
Treatment				0.003		0.077
BSC	12/15	2.3	0.028–4.572		1.00 (reference)
Adjuvant therapies	46/82	21.5	16.007–26.993		0.467 (0.201–1.085)

Notes: *O/N=observed death number/total patient number in each group. Bold values indicate statistical significance, P<0.05.

Abbreviations: BSC, best supportive care; MPM, malignant pleural mesothelioma; MST, median survival time; PS, performance status; HR, hazard ratio; SII, systemic immune–inflammation index.

Figure 1 The optimal cutoff value of pretreatment SII of malignant pleural mesothelioma patients based on ROC curve.

Abbreviations: ROC, receiver operating characteristic; SII, systemic immune–inflammation index.

Figure 2 Kaplan–Meier survival curves of ECOG PS, pretreatment SII and treatment strategy for malignant pleural mesothelioma patients.

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MST, median survival time; SII, systemic immune–inflammation index.

Table 2 Relationship between pretreatment SII and clinicopathological characteristics

Variables	SII<988.6	SII≥988.6	P-value
n (%)	n (%)
Age (years)			0.795
<65	35 (46.1)	41 (53.9)
≥65	9 (42.9)	12 (57.1)
Gender			0.337
Male	24 (41.4)	34 (58.6)
Female	20 (51.3)	19 (48.7)
Smoking			0.989
Never	29 (45.3)	35 (54.7)
Ever	15 (45.5)	18 (54.5)
PS			0.216*
<2	43 (47.3)	48 (52.7)
≥2	1 (16.7)	5 (83.3)
Tumor location			0.225
Left	17 (38.6)	27 (61.4)
Right	27 (50.9)	26 (49.1)
Pleural effusion			0.706
Absence	7 (50.0)	7 (50.0)
Presence	37 (44.6)	46 (55.4)
Weight loss			0.044
No	32 (40.5)	47 (59.5)
Yes	12 (66.7)	6 (33.3)

Notes: *Fisher’s Exact test. Bold values indicate statistical significance, P<0.05.

Abbreviations: PS, performance status; SII, systemic immune–inflammation index.